Loading...

Marks, Leonard S

Title(s)Professor-in-Residence, Urology
Phone43070
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Focal Laser Ablation of Prostate Cancer using MR/US Fusion
    NIH/NCI R01CA218547Jun 19, 2017 - May 31, 2022
    Role: Principal Investigator
    Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer
    NIH/NCI R01CA195505May 19, 2015 - Apr 30, 2017
    Role: Principal Investigator
    Biopsy Tracking and MRI Fusion to Enhance Imaging of Cancer Within the Prostate
    NIH/NCI R01CA158627Jul 5, 2011 - Jun 30, 2014
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Marks LS, Natarajan S. RE: Prostate Cancer Detection Rate of Free-hand versus 3D Template Mapping Biopsy Using an MRI/Ultrasound Fusion Device in Biopsy-Naïve Men. J Urol. 2020 May 04; 101097JU0000000000001124. PMID: 32364836.
      View in: PubMed
    2. Al Hussein Al Awamlh B, Marks LS, Sonn GA, Natarajan S, Fan RE, Gross MD, Mauer E, Banerjee S, Hectors S, Carlsson S, Margolis DJ, Hu JC. Multicenter analysis of clinical and MRI characteristics associated with detecting clinically significant prostate cancer in PI-RADS (v2.0) category 3 lesions. Urol Oncol. 2020 Apr 16. PMID: 32307327.
      View in: PubMed
    3. Marks LS, Kinnaird A. Editorial Comment. J Urol. 2020 Feb 20; 101097JU000000000000069202. PMID: 32077800.
      View in: PubMed
    4. Guorgui J, Kinnaird A, Jayadevan R, Priester AM, Arnold CW, Marks LS. An Electronic Form for Reporting Results of Targeted Prostate Biopsy: Urology Integrated Diagnostic Report (Uro-IDR). Urology. 2020 Apr; 138:188-193. PMID: 31978527.
      View in: PubMed
    5. Zhou SR, Priester AM, Jayadevan R, Johnson DC, Yang JJ, Ballon J, Natarajan S, Marks LS. Using spatial tracking with magnetic resonance imaging/ultrasound-guided biopsy to identify unilateral prostate cancer. BJU Int. 2020 Mar; 125(3):399-406. PMID: 31680423.
      View in: PubMed
    6. Kinnaird A, Marks LS. Editorial Comment. J Urol. 2020 01; 203(1):106-107. PMID: 31618155.
      View in: PubMed
    7. Zhou SR, Chang E, Patankar A, Huang J, Marks LS, Natarajan S. Prostate Cancer Detection Rate of Freehand versus 3-Dimensional Template Mapping Biopsy Using a Magnetic Resonance Imaging-Ultrasound Fusion Device in Biopsy Naïve Men. J Urol. 2019 Oct 09; 101097JU0000000000000587. PMID: 31596671.
      View in: PubMed
    8. Gross MD, Marks LS, Sonn GA, Green DA, Wang GJ, Shoag JE, Cabezon E, Margolis DJ, Robinson BD, Hu JC. Variation in Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy Outcomes in Asian American Men: A Multicenter Study. J Urol. 2020 03; 203(3):530-536. PMID: 31502942.
      View in: PubMed
    9. Jayadevan R, Felker ER, Kwan L, Barsa DE, Zhang H, Sisk AE, Delfin M, Marks LS. Magnetic Resonance Imaging-Guided Confirmatory Biopsy for Initiating Active Surveillance of Prostate Cancer. JAMA Netw Open. 2019 Sep 04; 2(9):e1911019. PMID: 31509206.
      View in: PubMed
    10. Felker ER, Raman SS, Lu DSK, Tuttle M, Margolis DJ, ElKhoury FF, Sayre J, Marks LS. Utility of Multiparametric MRI for Predicting Residual Clinically Significant Prostate Cancer After Focal Laser Ablation. AJR Am J Roentgenol. 2019 12; 213(6):1253-1258. PMID: 31361529.
      View in: PubMed
    11. Elkhoury FF, Felker ER, Kwan L, Sisk AE, Delfin M, Natarajan S, Marks LS. Comparison of Targeted vs Systematic Prostate Biopsy in Men Who Are Biopsy Naive: The Prospective Assessment of Image Registration in the Diagnosis of Prostate Cancer (PAIREDCAP) Study. JAMA Surg. 2019 Jun 12. PMID: 31188412.
      View in: PubMed
    12. Johnson DC, Yang JJ, Kwan L, Barsa DE, Mirak SA, Pooli A, Sadun T, Jayadevan R, Zhou S, Priester AM, Natarajan S, Bajgiran AM, Shakeri S, Sisk A, Felker ER, Raman SS, Marks LS, Reiter RE. Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection. Cancer. 2019 Sep 01; 125(17):2955-2964. PMID: 31042322.
      View in: PubMed
    13. Felker ER, Raman SS, Shakeri S, Mirak SA, Bajgiran AM, Kwan L, Khoshnoodi P, ElKhoury FF, Margolis DJA, Karow D, Lu DSK, White N, Marks LS. Utility of Restriction Spectrum Imaging Among Men Undergoing First-Time Biopsy for Suspected Prostate Cancer. AJR Am J Roentgenol. 2019 08; 213(2):365-370. PMID: 31039011.
      View in: PubMed
    14. Jayadevan R, Zhou S, Priester AM, Delfin M, Marks LS. Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy. J Vis Exp. 2019 04 09; (146). PMID: 31033955.
      View in: PubMed
    15. Simopoulos DN, Sisk AE, Priester A, Felker ER, Kwan L, Delfin MK, Reiter RE, Marks LS. Cancer core length from targeted biopsy: an index of prostate cancer volume and pathological stage. BJU Int. 2019 08; 124(2):275-281. PMID: 30694605.
      View in: PubMed
    16. Zhou SR, Simopoulos DN, Jayadevan R, Felker ER, Delfin MK, Barsa DE, Kwan L, Marks LS. Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer. Urology. 2019 04; 126:158-164. PMID: 30659903.
      View in: PubMed
    17. Jayadevan R, Marks LS. Exclusive MRI-targeted biopsy: not so fast. Lancet Oncol. 2019 01; 20(1):9-10. PMID: 30470503.
      View in: PubMed
    18. Marks LS. Editorial Comment. J Urol. 2018 12; 200(6):1240. PMID: 30172886.
      View in: PubMed
    19. Salmasi A, Faiena I, Wu J, Sisk AE, Sachveda A, Vandel JJ, Chamie K, Marks LS, Reiter RE. Radical prostatectomy then and now: Surgical overtreatment of prostate cancer is declining from 2009 to 2016 at a tertiary referral center. Urol Oncol. 2018 09; 36(9):401.e19-401.e25. PMID: 30064933.
      View in: PubMed
    20. Marks LS. Editorial Comment. J Urol. 2018 09; 200(3):563. PMID: 29913157.
      View in: PubMed
    21. Mesko S, Marks L, Ragab O, Patel S, Margolis DA, Demanes DJ, Kamrava M. Targeted Prostate Biopsy Gleason Score Heterogeneity and Implications for Risk Stratification. Am J Clin Oncol. 2018 05; 41(5):497-501. PMID: 27281263.
      View in: PubMed
    22. Priester A, Wu H, Khoshnoodi P, Schneider D, Zhang Z, Asvadi NH, Sisk A, Raman S, Reiter R, Grundfest W, Marks LS, Natarajan S. Registration Accuracy of Patient-Specific, Three-Dimensional-Printed Prostate Molds for Correlating Pathology With Magnetic Resonance Imaging. IEEE Trans Biomed Eng. 2019 01; 66(1):14-22. PMID: 29993431.
      View in: PubMed
    23. Salmasi A, Said J, Shindel AW, Khoshnoodi P, Felker ER, Sisk AE, Grogan T, McCullough D, Bennett J, Bailey H, Lawrence HJ, Elashoff DA, Marks LS, Raman SS, Febbo PG, Reiter RE. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy. J Urol. 2018 09; 200(3):564-572. PMID: 29524506.
      View in: PubMed
    24. Elkhoury FF, Simopoulos DN, Marks LS. MR-guided biopsy and focal therapy: new options for prostate cancer management. Curr Opin Urol. 2018 03; 28(2):93-101. PMID: 29232269.
      View in: PubMed
    25. Marks LS. Editorial Comment. J Urol. 2018 04; 199(4):981-982. PMID: 29360445.
      View in: PubMed
    26. Golan R, Bernstein A, Sedrakyan A, Daskivich TJ, Du DT, Ehdaie B, Fisher B, Gorin MA, Grunberger I, Hunt B, Jiang HH, Kim HL, Marinac-Dabic D, Marks LS, McClure TD, Montgomery JS, Parekh DJ, Punnen S, Scionti S, Viviano CJ, Wei JT, Wenske S, Wysock JS, Rewcastle J, Carol M, Oczachowski M, Hu JC. Development of a Nationally Representative Coordinated Registry Network for Prostate Ablation Technologies. J Urol. 2018 06; 199(6):1488-1493. PMID: 29307684.
      View in: PubMed
    27. Calais J, Fendler WP, Eiber M, Gartmann J, Chu FI, Nickols NG, Reiter RE, Rettig MB, Marks LS, Ahlering TE, Huynh LM, Slavik R, Gupta P, Quon A, Allen-Auerbach MS, Czernin J, Herrmann K. Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med. 2018 03; 59(3):434-441. PMID: 29242398.
      View in: PubMed
    28. Elkhoury FF, Simopoulos DN, Marks LS. Targeted Prostate Biopsy in the Era of Active Surveillance. Urology. 2018 Feb; 112:12-19. PMID: 28962878.
      View in: PubMed
    29. Felker ER, Raman SS, Margolis DJ, Lu DSK, Shaheen N, Natarajan S, Sharma D, Huang J, Dorey F, Marks LS. Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? AJR Am J Roentgenol. 2017 Dec; 209(6):1272-1277. PMID: 28858541.
      View in: PubMed
    30. Nassiri N, Chang E, Lieu P, Priester AM, Margolis DJA, Huang J, Reiter RE, Dorey FJ, Marks LS, Natarajan S. Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. J Urol. 2018 02; 199(2):453-458. PMID: 28830754.
      View in: PubMed
    31. Chang E, Jones TA, Natarajan S, Sharma D, Simopoulos D, Margolis DJ, Huang J, Dorey FJ, Marks LS. Value of Tracking Biopsy in Men Undergoing Active Surveillance of Prostate Cancer. J Urol. 2018 01; 199(1):98-105. PMID: 28728993.
      View in: PubMed
    32. Jones TA, Chin J, Mcleod D, Barkin J, Pantuck A, Marks LS. High Intensity Focused Ultrasound for Radiorecurrent Prostate Cancer: A North American Clinical Trial. J Urol. 2018 01; 199(1):133-139. PMID: 28652121.
      View in: PubMed
    33. Simopoulos DN, Natarajan S, Jones TA, Fendler WP, Sisk AE, Marks LS. Targeted Prostate Biopsy Using 68Gallium PSMA-PET/CT for Image Guidance. Urol Case Rep. 2017 Sep; 14:11-14. PMID: 28607878.
      View in: PubMed
    34. Natarajan S, Jones TA, Priester AM, Geoghegan R, Lieu P, Delfin M, Felker E, Margolis DJA, Sisk A, Pantuck A, Grundfest W, Marks LS. Focal Laser Ablation of Prostate Cancer: Feasibility of Magnetic Resonance Imaging-Ultrasound Fusion for Guidance. J Urol. 2017 10; 198(4):839-847. PMID: 28396184.
      View in: PubMed
    35. Huen KH, Nseyo U, Marks LS. The First Filmed Prostatectomy, 1917: 100 Years of Movies in Urological Education. Urology. 2017 Jul; 105:29-32. PMID: 28363740.
      View in: PubMed
    36. Jones TA, Marks LS. Re: A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population. Eur Urol. 2017 06; 71(6):986-987. PMID: 28233592.
      View in: PubMed
    37. Verma S, Rosenkrantz AB, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. Commentary regarding a recent collaborative consensus statement addressing prostate MRI and MRI-targeted biopsy in patients with a prior negative prostate biopsy. Abdom Radiol (NY). 2017 Feb; 42(2):346-349. PMID: 27670878.
      View in: PubMed
    38. Marks LS. Editorial Comment. Urology. 2017 04; 102:195-196. PMID: 28034528.
      View in: PubMed
    39. Patel S, Demanes DJ, Ragab O, Zhang M, Veruttipong D, Nguyen K, Park SJ, Marks L, Pantuck A, Steinberg M, Kamrava M. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):299-305. PMID: 27965117.
      View in: PubMed
    40. Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ. Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int. 2017 07; 120(1):61-68. PMID: 27743489.
      View in: PubMed
    41. Palapattu GS, Salami SS, Cani AK, Hovelson DH, Lazo de la Vega L, Vandenberg KR, Bratley JV, Liu CJ, Kunju LP, Montgomery JS, Morgan TM, Natarajan S, Huang J, Tomlins SA, Marks LS. Molecular Profiling to Determine Clonality of Serial Magnetic Resonance Imaging/Ultrasound Fusion Biopsies from Men on Active Surveillance for Low-Risk Prostate Cancer. Clin Cancer Res. 2017 Feb 15; 23(4):985-991. PMID: 28031426.
      View in: PubMed
    42. Jones TA, Natarajan S, Priester AM, Marks LS. Focal Laser Ablation of Prostate Cancer. Urology. 2017 Jan; 99:e21-e22. PMID: 27720973.
      View in: PubMed
    43. Marks LS. Some prostate cancers are invisible to magnetic resonance imaging! BJU Int. 2016 10; 118(4):492-3. PMID: 27625328.
      View in: PubMed
    44. Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, Marks LS. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. J Urol. 2017 03; 197(3 Pt 1):632-639. PMID: 27639713.
      View in: PubMed
    45. Jones TA, Radtke JP, Hadaschik B, Marks LS. Optimizing safety and accuracy of prostate biopsy. Curr Opin Urol. 2016 09; 26(5):472-80. PMID: 27214580.
      View in: PubMed
    46. Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, Huang J, Grundfest W, Marks LS. Magnetic Resonance Imaging Underestimation of Prostate Cancer Geometry: Use of Patient Specific Molds to Correlate Images with Whole Mount Pathology. J Urol. 2017 02; 197(2):320-326. PMID: 27484386.
      View in: PubMed
    47. Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 12; 196(6):1613-1618. PMID: 27320841.
      View in: PubMed
    48. Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, Azzouzi AR, Emberton M. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. J Urol. 2016 Oct; 196(4):1096-104. PMID: 27291652.
      View in: PubMed
    49. Felker ER, Margolis DJ, Nassiri N, Marks LS. Prostate cancer risk stratification with magnetic resonance imaging. Urol Oncol. 2016 07; 34(7):311-9. PMID: 27040381.
      View in: PubMed
    50. Tan HJ, Marks LS, Hoyt MA, Kwan L, Filson CP, Macairan M, Lieu P, Litwin MS, Stanton AL. The Relationship between Intolerance of Uncertainty and Anxiety in Men on Active Surveillance for Prostate Cancer. J Urol. 2016 06; 195(6):1724-30. PMID: 26872841.
      View in: PubMed
    51. Filson CP, Natarajan S, Margolis DJ, Huang J, Lieu P, Dorey FJ, Reiter RE, Marks LS. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016 Mar 15; 122(6):884-92. PMID: 26749141.
      View in: PubMed
    52. Natarajan S, Raman S, Priester AM, Garritano J, Margolis DJ, Lieu P, Macairan ML, Huang J, Grundfest W, Marks LS. Focal Laser Ablation of Prostate Cancer: Phase I Clinical Trial. J Urol. 2016 07; 196(1):68-75. PMID: 26748164.
      View in: PubMed
    53. Felker ER, Wu J, Natarajan S, Margolis DJ, Raman SS, Huang J, Dorey F, Marks LS. Serial Magnetic Resonance Imaging in Active Surveillance of Prostate Cancer: Incremental Value. J Urol. 2016 May; 195(5):1421-1427. PMID: 26674305.
      View in: PubMed
    54. Bockholt N, Marks LS. Targeted prostate biopsy using magnetic resonance imaging-ultrasound fusion. Asian J Androl. 2015 Nov-Dec; 17(6):870-3. PMID: 26289396.
      View in: PubMed
    55. Rakow-Penner RA, White NS, Margolis DJA, Parsons JK, Schenker-Ahmed N, Kuperman JM, Bartsch H, Choi HW, Bradley WG, Shabaik A, Huang J, Liss MA, Marks L, Kane CJ, Reiter RE, Raman SS, Karow DS, Dale AM. Prostate diffusion imaging with distortion correction. Magn Reson Imaging. 2015 Nov; 33(9):1178-1181. PMID: 26220859.
      View in: PubMed
    56. Nassiri N, Natarajan S, Margolis DJ, Marks LS. Targeted Prostate Biopsy: Lessons Learned Midst the Evolution of a Disruptive Technology. Urology. 2015 Sep; 86(3):432-8. PMID: 26166671.
      View in: PubMed
    57. Kamrava M, Kishan AU, Margolis DJ, Huang J, Dorey F, Lieu P, Kupelian PA, Marks LS. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. Pract Radiat Oncol. 2015 Nov-Dec; 5(6):411-6. PMID: 26059510.
      View in: PubMed
    58. Filson CP, Marks LS, Litwin MS. Expectant management for men with early stage prostate cancer. CA Cancer J Clin. 2015 Jul-Aug; 65(4):265-82. PMID: 25958817.
      View in: PubMed
    59. Kamrava M, Hegde JV, Abgaryan N, Chang E, Le JD, Wang J, Kupelian PA, Marks LS. Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists? BJU Int. 2016 Apr; 117(4):584-91. PMID: 25684394.
      View in: PubMed
    60. Marks LS. Significance of Change in Gleason Grade in Patients on Active Surveillance for Prostate Cancer. J Urol. 2015 Jul; 194(1):8-9. PMID: 25892137.
      View in: PubMed
    61. Kaplan AL, Ehrlich RM, Marks LS, Walsh PC, Bloom DA, Hu JC. Joseph J. Kaufman: renaissance man. Urology. 2015 Mar; 85(3):487-90. PMID: 25733256.
      View in: PubMed
    62. Liss MA, White NS, Parsons JK, Schenker-Ahmed NM, Rakow-Penner R, Kuperman JM, Bartsch H, Choi HW, Mattrey RF, Bradley WG, Shabaik A, Huang J, Margolis DJ, Raman SS, Marks LS, Kane CJ, Reiter RE, Dale AM, Karow DS. MRI-Derived Restriction Spectrum Imaging Cellularity Index is Associated with High Grade Prostate Cancer on Radical Prostatectomy Specimens. Front Oncol. 2015; 5:30. PMID: 25741473.
      View in: PubMed
    63. Valerio M, Donaldson I, Emberton M, Ehdaie B, Hadaschik BA, Marks LS, Mozer P, Rastinehad AR, Ahmed HU. Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. Eur Urol. 2015 Jul; 68(1):8-19. PMID: 25454618.
      View in: PubMed
    64. Le JD, Tan N, Shkolyar E, Lu DY, Kwan L, Marks LS, Huang J, Margolis DJ, Raman SS, Reiter RE. Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. Eur Urol. 2015 Mar; 67(3):569-76. PMID: 25257029.
      View in: PubMed
    65. Priester A, Natarajan S, Le JD, Garritano J, Radosavcev B, Grundfest W, Margolis DJ, Marks LS, Huang J. A system for evaluating magnetic resonance imaging of prostate cancer using patient-specific 3D printed molds. Am J Clin Exp Urol. 2014; 2(2):127-35. PMID: 25374914.
      View in: PubMed
    66. Sonn GA, Filson CP, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. Initial experience with electronic tracking of specific tumor sites in men undergoing active surveillance of prostate cancer. Urol Oncol. 2014 Oct; 32(7):952-7. PMID: 25027689.
      View in: PubMed
    67. Le JD, Huang J, Marks LS. Targeted prostate biopsy: value of multiparametric magnetic resonance imaging in detection of localized cancer. Asian J Androl. 2014 Jul-Aug; 16(4):522-9. PMID: 24589455.
      View in: PubMed
    68. Le JD, Stephenson S, Brugger M, Lu DY, Lieu P, Sonn GA, Natarajan S, Dorey FJ, Huang J, Margolis DJ, Reiter RE, Marks LS. Magnetic resonance imaging-ultrasound fusion biopsy for prediction of final prostate pathology. J Urol. 2014 Nov; 192(5):1367-73. PMID: 24793118.
      View in: PubMed
    69. Stephenson SK, Chang EK, Marks LS. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am. 2014 May; 41(2):315-26. PMID: 24725492.
      View in: PubMed
    70. Partin AW, Van Neste L, Klein EA, Marks LS, Gee JR, Troyer DA, Rieger-Christ K, Jones JS, Magi-Galluzzi C, Mangold LA, Trock BJ, Lance RS, Bigley JW, Van Criekinge W, Epstein JI. Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol. 2014 Oct; 192(4):1081-7. PMID: 24747657.
      View in: PubMed
    71. Marks LS. Improving risk stratification in patients with prostate cancer managed by active surveillance: nomogram predicting the risk of biopsy progression. BJU Int. 2014 Apr; 113(4):E13-4. PMID: 24629086.
      View in: PubMed
    72. Hu JC, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Sonn G, Dorey FJ, Marks LS. Targeted prostate biopsy in select men for active surveillance: do the Epstein criteria still apply? J Urol. 2014 Aug; 192(2):385-90. PMID: 24512956.
      View in: PubMed
    73. Sonn GA, Margolis DJ, Marks LS. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol. 2014 Aug; 32(6):903-11. PMID: 24239473.
      View in: PubMed
    74. Albertsen PC, Marks LS. MRI before prostate biopsy--yes or no? J Urol. 2013 Dec; 190(6):1978-80. PMID: 23994537.
      View in: PubMed
    75. Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol. 2013 Oct; 64(4):544-52. PMID: 23537686.
      View in: PubMed
    76. Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, Huang J, Dorey FJ, Reiter RE, Marks LS. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol. 2014 Apr; 65(4):809-15. PMID: 23523537.
      View in: PubMed
    77. Kamrava M, Chung MP, Kayode O, Wang J, Marks L, Kupelian P, Steinberg M, Park SJ, Demanes DJ. Focal high-dose-rate brachytherapy: a dosimetric comparison of hemigland vs. conventional whole-gland treatment. Brachytherapy. 2013 Sep-Oct; 12(5):434-41. PMID: 23406987.
      View in: PubMed
    78. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective a(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2013 Jan; 189(1 Suppl):S122-8. PMID: 23234617.
      View in: PubMed
    79. Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013 Jan; 23(1):43-50. PMID: 23138468.
      View in: PubMed
    80. Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, Huang J, Dorey FJ, Marks LS. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013 Jan; 189(1):86-91. PMID: 23158413.
      View in: PubMed
    81. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2013 Feb; 63(2):201-9. PMID: 22854248.
      View in: PubMed
    82. Natarajan S, Marks LS, Margolis DJ, Huang J, Macairan ML, Lieu P, Fenster A. Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol. 2011 May-Jun; 29(3):334-42. PMID: 21555104.
      View in: PubMed
    83. Xie C, Kim HJ, Haw JG, Kalbasi A, Gardner BK, Li G, Rao J, Chia D, Liong M, Punzalan RR, Marks LS, Pantuck AJ, de la Taille A, Wang G, Mukouyama H, Zeng G. A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med. 2011 Apr 19; 9:43. PMID: 21504557.
      View in: PubMed
    84. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, Slawin KM, Marks LS, Loeb S, Broyles DL, Shin SS, Cruz AB, Chan DW, Sokoll LJ, Roberts WL, van Schaik RH, Mizrahi IA. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011 May; 185(5):1650-5. PMID: 21419439.
      View in: PubMed
    85. Marks LS, Huang J. Words of wisdom. Re: copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Eur Urol. 2010 Apr; 57(4):727-8. PMID: 20965042.
      View in: PubMed
    86. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009 Dec; 74(6):1318-22. PMID: 19815265.
      View in: PubMed
    87. Marks LS, Kaplan SA. Should testosterone replacement be given to men with large prostates? J Urol. 2009 Nov; 182(5):2109-11. PMID: 19758636.
      View in: PubMed
    88. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol. 2009 Jun; 181(6):2634-40. PMID: 19371887.
      View in: PubMed
    89. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009 Jul; 56(1):48-56. PMID: 19375844.
      View in: PubMed
    90. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009 Oct; 56(4):659-67. PMID: 19304372.
      View in: PubMed
    91. Marks LS. Words of wisdom. Re: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Eur Urol. 2009 Mar; 55(3):750-1. PMID: 19650234.
      View in: PubMed
    92. Marks LS, Mostaghel EA, Nelson PS. Prostate tissue androgens: history and current clinical relevance. Urology. 2008 Aug; 72(2):247-54. PMID: 18502483.
      View in: PubMed
    93. Marks LS. Editorial comment. J Urol. 2008 May; 179(5):1744-5. PMID: 18343450.
      View in: PubMed
    94. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008 Apr; 179(4):1587-92. PMID: 18295257.
      View in: PubMed
    95. Marks LS, Roehrborn CG, Wolford E, Wilson TH. The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment response. J Urol. 2007 Apr; 177(4):1408-13. PMID: 17382742.
      View in: PubMed
    96. Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007 Mar; 69(3):532-5. PMID: 17382159.
      View in: PubMed
    97. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, Veltri RW, Makarov DV, Partin AW, Bostwick DG, Macairan ML, Nelson PS. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006 Nov 15; 296(19):2351-61. PMID: 17105798.
      View in: PubMed
    98. Marks LS, Roehrborn CG, Andriole GL. Prevention of benign prostatic hyperplasia disease. J Urol. 2006 Oct; 176(4 Pt 1):1299-306. PMID: 16952616.
      View in: PubMed
    99. Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol. 2006 Sep; 176(3):868-74. PMID: 16890642.
      View in: PubMed
    100. Marks LS, Hess DL, Dorey FJ, Macairan ML. Prostatic tissue testosterone and dihydrotestosterone in African-American and white men. Urology. 2006 Aug; 68(2):337-41. PMID: 16904448.
      View in: PubMed
    101. Marks LS. Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease. Curr Urol Rep. 2006 Jul; 7(4):293-303. PMID: 16930501.
      View in: PubMed
    102. Marks LS, Kojima M, Demarzo A, Heber D, Bostwick DG, Qian J, Dorey FJ, Veltri RW, Mohler JL, Partin AW. Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissue. Urology. 2004 Oct; 64(4):765-71. PMID: 15491717.
      View in: PubMed
    103. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology. 2004 Apr; 63(4):709-15. PMID: 15072886.
      View in: PubMed
    104. Marks LS, Roehrborn CG, Gittelman M, Kim D, Forrest J, Jacobs S. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology. 2003 Nov; 62(5):888-93. PMID: 14624914.
      View in: PubMed